Patients who complete study T1249-102 (must be currently failing a T-20 containing regimen
to participate in this study) will receive T-1249 at a dose of 200mg daily in combination
with a background antiretroviral regimen for 96 weeks. Only patients that participated in
study T1249-102 can participate in study T1249-105.
- Completion T1249-102;
- Currently failing a T-20 containing regimen
- Non-completion of T1249-102.